Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus

被引：23

作者：

Fitzgibbon, JE

John, JF

Delucia, JL

Dubin, DT

机构：

[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA

[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Allergy Immunol & Infect Dis, Piscataway, NJ 08854 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1998年 / 42卷 / 08期

关键词：

D O I：

10.1128/AAC.42.8.2122

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A total of 201 Staphylococcus aureus isolates were surveyed for susceptibility to ciprofloxacin and trovafloxacin. Of 66 methicillin-resistant isolates, 89% were ciprofloxacin resistant and 6% were also trovafloxacin resistant. Trovafloxacin-resistant strains had unusual patterns of quinoline resistance mutations in DNA topoisomerase genes, including two mutations in the A subunit (encoded by grlA) of topoisomerase IV.

引用

页码：2122 / 2124

页数：3

共 18 条

[1] Trends in bacterial resistance to fluoroquinolones [J].

Acar, JF ;

Goldstein, FW .

CLINICAL INFECTIOUS DISEASES, 1997, 24 :S67-S73

[2] Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin [J].

Bonilla, HF ;

Zarins, LT ;

Bradley, SF ;

Kauffman, CA .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 26 (01) :17-21

[3] ANTISTAPHYLOCOCCAL ACTIVITIES OF SPARFLOXACIN (CI-978-AT-4140), OFLOXACIN, AND CIPROFLOXACIN [J].

CHAUDHRY, AZ ;

KNAPP, CC ;

SIERRAMADERO, J ;

WASHINGTON, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) :1843-1845

[4] Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae [J].

Deguchi, T ;

Fukuoka, A ;

Yasuda, M ;

Nakano, M ;

Ozeki, S ;

Kanematsu, E ;

Nishino, Y ;

Ishihara, S ;

Ban, Y ;

Kawada, Y .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :699-701

[5] DNA gyrase, topoisomerase IV, and the 4-quinolones [J].

Drlica, K ;

Zhao, XL .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) :377-+

[6] Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections [J].

Endtz, HP ;

Mouton, JW ;

denHollander, JG ;

vandenBraak, N ;

Verbrugh, HA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1146-1149

[7] CLONING AND PRIMARY STRUCTURE OF STAPHYLOCOCCUS-AUREUS DNA TOPOISOMERASE-IV - A PRIMARY TARGET OF FLUOROQUINOLONES [J].

FERRERO, L ;

CAMERON, B ;

MANSE, B ;

LAGNEAUX, D ;

CROUZET, J ;

FAMECHON, A ;

BLANCHE, F .

MOLECULAR MICROBIOLOGY, 1994, 13 (04) :641-653

[8] ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS [J].

FERRERO, L ;

CAMERON, B ;

CROUZET, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1554-1558

[9] Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli [J].

Heisig, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :879-885

[10] PRELIMINARY INTERPRETIVE CRITERIA FOR IN-VITRO SUSCEPTIBILITY TESTING OF CP-99219 BY DILUTION AND DISK DIFFUSION METHODS [J].

JONES, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 20 (03) :167-170

← 1 2 →